Contact information

Email
freddie.hamdy@nds.ox.ac.uk

Telephone
+44 (0)1865 617123
Fax +44 (0)1865 617125

PA
Nicky Iyer
nicky.iyer@nds.ox.ac.uk

LOCATION

Old Road Campus Research Building (off Roosevelt Drive), Churchill Hospital, Headington, Oxford, OX3 7DQ

Research groups

Colleges

Balliol College

Biography

I joined Oxford in October 2008 as Head of the Nuffield Department of Surgery, Nuffield Professor of Surgery, Professor of Urology and Honorary Consultant Urological Surgeon at the Oxford Radcliffe Hospitals as well as Fellow of Balliol College. I spent the past 10 years as founding Chair of Urology and was Director of the Division of Clinical Sciences, then Head of Oncology at the University of Sheffield. I trained in Surgery and Urology at Liverpool, Sheffield and Newcastle.

I have authored over 200 peer-reviewed articles, and raised to date over £40m in peer-reviewed grants.

Memberships

British Association of Urological Surgeons
British Medical Association
European Association of Urology
American Urological Association
Association of Academic European Urologists
Deutsche Gesellschaft für Urologie (German Urological Society)

Freddie Hamdy CBE

MBChB, LRCP-LRCSEd, LRCPSGlasg, FRCSEd, FRCSEng, MD (Shef), MA (Oxon) FRCSEd (Urol), FMedSci

Head of Department

Nuffield Professor of Surgery
Professor of Urology

My research focuses on management of urological malignancies, in particular prostate and bladder cancer.

Each year about 10,000 people in the UK are diagnosed with bladder cancer and about 40,000 men are diagnosed with prostate cancer, with prostate cancer being the the most common cancer in men.

My laboratory interest is the mechanisms of invasion/metastasis in prostate cancer and the interaction between primary prostate cancer cells and the bone microenvironment, as well as epigenetics of bladder cancer.

My clinical research interest is to provide evidence of treatment effectiveness in prostate cancer through large randomized controlled trials.

I am the Chief Investigator of many studies including the ProtecT (Prostate testing for cancer and Treatment) study of case-finding and randomised controlled trial of treatment effectiveness in prostate cancer - the largest of its kind worldwide. I am also establishing various multidisciplinary research platforms at Oxford and introducing, with colleagues, a new centre for evaluation of minimally invasive technology including robotic surgery.

Awards

1995 - AUA/EAU Academic Exchange Fellowship
1996 - EAU Crystal Matula Award
2001 - Golden Telescope award, BAUS
2007 - Fellow of the Academy of Medical Sciences
2012 - St Peter’s Medal, BAUS
2017 - NIHR Senior Investigator Emeritus
2015 - Elected Member, American Association of GU surgeons
2018 - Marberger Prize, Association of Academic European Urologists (AAEU)
2018 - Willy Gregoir Medal, European Association of Urology
2022 - Medal for Excellence Award, British Association of Surgical Oncology (BASO)
2022 - Laurent Boccon-Gibod Medal, Association of Academic European Urologists (AAEU)
2024 - CBE (Commander of the Order of the British Empire) – for services to surgical and cancer sciences

View publications on PubMed

Key publications

First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy.

Hamdy FC. et al, (2024), Eur J Nucl Med Mol Imaging, 51, 3009 - 3025

Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.

Martin RM. et al, (2024), JAMA, 331, 1460 - 1470

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features.

Rao S. et al, (2024), Genome Med, 16

Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Hamdy FC. et al, (2023), N Engl J Med, 388, 1547 - 1558

Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment.

Donovan JL. et al, (2023), NEJM Evid, 2

Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial.

Sooriakumaran P. et al, (2022), BJU Int, 130, 43 - 53

prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial.

Donovan JL. et al, (2018), J Clin Epidemiol, 96, 35 - 46

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.

Martin RM. et al, (2018), JAMA, 319, 883 - 895

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Hamdy FC. et al, (2016), N Engl J Med, 375, 1415 - 1424

Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Donovan JL. et al, (2016), N Engl J Med, 375, 1425 - 1437

Recent publications

Local anaesthetic transperineal biopsy versus transrectal prostate biopsy in prostate cancer detection (TRANSLATE): a multicentre, randomised, controlled trial.

Bryant RJ. et al, (2025), Lancet Oncol, 26, 583 - 595

Clonal phylogenies inferred from bulk, single cell, and spatial transcriptomic analysis of epithelial cancers.

Erickson A. et al, (2025), PLoS One, 20

Mapping clonal heterogeneity and stromal dynamics in prostate cancer

Figiel S. et al, (2025), CANCER RESEARCH, 85

Stress-Induced Rab11a-Exosomes Induce Amphiregulin-Mediated Cetuximab Resistance in Colorectal Cancer (vol 13, e12465, 2024)

Mason JD. et al, (2025), JOURNAL OF EXTRACELLULAR VESICLES, 14

Integrating multiparametric MRI with spatial transcriptomics to identify "Radio-Spatial Genomic" features of prostate cancer using artificial intelligence

Anbarasan T. et al, (2025), CANCER RESEARCH, 85

PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.

Srinivasan S. et al, (2024), Nat Commun, 15

Flourine-18 prostate-specific membrane antigen-1007 positron emission tomography imaging in staging of primary and secondary prostate cancer - a retrospective observational cohort study

Byrne M. et al, (2024), JU Open Plus, 2

Comprehensive National Survey of Prostate-specific Antigen Testing and Prostate Cancer Management in France: Uncovering Regional and Temporal Disparities.

Cussenot O. et al, (2024), Eur Urol Oncol, 7, 978 - 981

'Case of the Month' from the Department of Urology, Oxford University Hospitals, Oxford, UK: stereotactic radiotherapy to the vas deferens for PSMA-PET CT detected local recurrence 10 years after radical prostatectomy.

Bates AS. et al, (2024), BJU Int, 134, 377 - 379

First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy.

Hamdy FC. et al, (2024), Eur J Nucl Med Mol Imaging, 51, 3009 - 3025

Delphi consensus project on prostate-specific membrane antigen (PSMA)-targeted surgery-outcomes from an international multidisciplinary panel.

Berrens A-C. et al, (2024), Eur J Nucl Med Mol Imaging, 51, 2893 - 2902

Re: Annika Herlemann, Janet E. Cowan, Samuel L. Washington 3rd, et al. Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer. Eur Urol. 2024;85:565-573.

Cussenot O. et al, (2024), Eur Urol, 86, e48 - e49

Screening and active surveillance in prostate cancer: the dilemma continues.

Hamdy FC. et al, (2024), BJU Int, 134, 1 - 2

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease.

Charlton PV. et al, (2024), Prostate, 84, 977 - 990

Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer.

Mason JD. et al, (2024), J Extracell Vesicles, 13

Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.

Martin RM. et al, (2024), JAMA, 331, 1460 - 1470

Genomic evolution shapes prostate cancer disease type.

Woodcock DJ. et al, (2024), Cell Genom, 4

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features.

Rao S. et al, (2024), Genome Med, 16

Reply to Bernardo Rocco and Maria Chiara Sighinolfi's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.

Hamdy FC. and Donovan JL., (2024), Eur Urol, 85, e41 - e42

Reply to Greg Shaw, John D. Kelly, and Monique J. Roobol's Letter to the Editor re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547-58.

Hamdy FC. and Donovan JL., (2024), Eur Urol, 85, e54 - e55

Stress-induced extracellular vesicles promote EGFR-ERK dependent growth and cetuximab resistance in colorectal cancer

Mason J. et al, (2024), BRITISH JOURNAL OF SURGERY, 111

EXPLORING STROMAL DYNAMICS IN PROSTATE CANCER: INSIGHTS FROM SPATIAL TRANSCRIPTOMIC ANALYSES

Figiel S. et al, (2024), JOURNAL OF UROLOGY, 211, E181 - E181

SPATIAL TRANSCRIPTOMIC CLONAL DECONVOLUTION IDENTIFIES THE 'LETHAL CLONE' IN PROSTATE CANCER AS DEFINED BY ABILITY TO METASTASIZE TO LYMPH NODES

Yin W. et al, (2024), JOURNAL OF UROLOGY, 211, E182 - E182

Endemic statistical paradoxes in epidemiologic studies distort knowledge on prostate cancer: mitigation and caution of fallacies in prostate cancer causal epidemiological studies.

Cussenot O. et al, (2023), Curr Opin Urol, 33, 421 - 427

ligning germline and somatic mutations in prostate cancer. Are genetics changing practice?

Cussenot O. et al, (2023), BJU Int, 132, 472 - 484

Decision Making in Prostate Cancer.

Nadamuni M. et al, (2023), N Engl J Med, 389, 1335 - 1338

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures.

Figiel S. et al, (2023), Mol Cancer, 22

Molecular analysis of archival diagnostic prostate cancer biopsies identifies genomic similarities in cases with progression post-radiotherapy, and those with de novo metastatic disease

Charlton P. et al, (2023)

Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types.

Rao SR. et al, (2023), Int J Mol Sci, 24

Geometric Anatomy Basis for Safe and Effective Focal Ablation of Prostate Cancer by Irreversible Electroporation (IRE)

Cussenot O. et al, (2023), Anatomia, 2, 232 - 242

Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. Reply.

Hamdy FC. and Donovan JL., (2023), N Engl J Med, 389

Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Thorn JC. et al, (2023), BMC Health Serv Res, 23

Rbf/E2F1 control growth and endoreplication via steroid-independent Ecdysone Receptor signalling in Drosophila prostate-like secondary cells.

Sekar A. et al, (2023), PLoS Genet, 19

Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition.

Rodriguez-Martin B. et al, (2023), Nat Genet, 55

Correction: The landscape of viral associations in human cancers.

Zapatka M. et al, (2023), Nat Genet, 55

Clinical performance of magnetic resonance imaging and biomarkers for prostate cancer diagnosis in men at high genetic risk.

Cussenot O. et al, (2023), BJU Int, 131, 745 - 754

The Detection of Prostate Cancer With Magnetic Resonance Imaging-targeted Prostate Biopsies Is Superior With the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study. Letter

Bryant RJ. et al, (2023), Journal of Urology, 209

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of heterogeneity on genomic signature scoring

Figiel S. et al, (2023)

Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole genome sequencing with histopathological features

Rao S. et al, (2023)

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of heterogeneity on genomic signature scoring

Figiel S. et al, (2023), EUROPEAN UROLOGY, 83

Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.

Keeney E. et al, (2022), Pharmacoeconomics, 40, 1207 - 1220

The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.

Buhigas C. et al, (2022), Mol Cancer, 21

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).

Lane JA. et al, (2022), BJU Int, 130, 370 - 380

Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.

Burns D. et al, (2022), Eur Urol, 82, 201 - 211

Spatially resolved clonal copy number alterations in benign and malignant tissue.

Erickson A. et al, (2022), Nature, 608, 360 - 367

Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial.

Sooriakumaran P. et al, (2022), BJU Int, 130, 43 - 53

mated quality assessment of large digitised histology cohorts by artificial intelligence.

Haghighat M. et al, (2022), Sci Rep, 12

Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival.

Whitburn J. et al, (2022), Sci Adv, 8

Prostate-Specific Antigen Testing for Prostate Cancer Screening-Is the Message Getting Through?

Hamdy FC., (2022), JAMA Oncol, 8, 47 - 49

Precision surgery: the role of intra-operative real-time image guidance - outcomes from a multidisciplinary European consensus conference.

Dell'Oglio P. et al, (2022), Am J Nucl Med Mol Imaging, 12, 74 - 80

The spatial landscape of clonal somatic mutations in benign and malignant tissue

Erickson A. et al, (2022), CANCER RESEARCH, 82

prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.

Bancroft EK. et al, (2021), Lancet Oncol, 22, 1618 - 1631

Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.

Farolfi A. et al, (2021), Eur Urol Oncol, 4, 714 - 730

Placebo comparator group selection and use in surgical trials: the ASPIRE project including expert workshop.

Beard DJ. et al, (2021), Health Technol Assess, 25, 1 - 52

Local anaesthetic transperineal (LATP) prostate biopsy using a probe-mounted transperineal access system: a multicentre prospective outcome analysis.

Lopez JF. et al, (2021), BJU Int, 128, 311 - 318

Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.

Sjoberg HT. et al, (2021), Br J Cancer, 125, 534 - 546

Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

Conti DV. et al, (2021), Nat Genet, 53

Men's experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study.

Sutton E. et al, (2021), Cancer Causes Control, 32, 261 - 269

Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.

Huynh-Le M-P. et al, (2021), Nat Commun, 12

modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance.

Merriel SWD. et al, (2021), BMC Urol, 21

Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study.

Catto JWF. et al, (2021), J Clin Oncol, 39, 202 - 214

Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management

Ranasinha N. et al, (2021), BJUI Compass, n/a

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.

Conti DV. et al, (2021), Nat Genet, 53, 65 - 75

Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management.

Ranasinha N. et al, (2021), BJUI Compass, 2, 13 - 23

Organochlorine pesticide exposure and risk of prostate cancer development and progression: a systematic review

Brureau L. et al, (2021), F1000Research, 10

Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.

Bailey MH. et al, (2020), Nat Commun, 11

Outreach and Influence of Surgical Societies' Recommendations on Minimally Invasive Surgery During the COVID-19 Pandemic-An Anonymized International Urologic Expert Inquiry.

Boehm K. et al, (2020), Urology, 145, 73 - 78

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.

Sanghera S. et al, (2020), BMC Cancer, 20

The effect of sample size on polygenic hazard models for prostate cancer.

Karunamuni RA. et al, (2020), Eur J Hum Genet, 28, 1467 - 1475

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.

Bailey MH. et al, (2020), Nat Commun, 11

Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial.

Wade J. et al, (2020), BMJ Open, 10

Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.

Philippou Y. et al, (2020), Br J Cancer, 123, 1089 - 1100

Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data.

Huynh-Le M-P. et al, (2020), Cancer Epidemiol Biomarkers Prev, 29, 1731 - 1738

Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330].

Neal DE. et al, (2020), Eur Urol, 78, e139 - e143

Correction.

(2020), J Mol Diagn, 22

Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.

Sathianathen NJ. et al, (2020), Eur Urol, 78, 402 - 414

The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.

Noble SM. et al, (2020), Br J Cancer, 123, 1063 - 1070

ctive monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

Hamdy FC. et al, (2020), Health Technol Assess, 24, 1 - 176

new Editorial Team for the BJU International….

Hamdy FC., (2020), BJU Int, 126, 213 - 214

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.

Cappuccini F. et al, (2020), J Immunother Cancer, 8

Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration.

Rao SR. et al, (2020), J Mol Diagn, 22, 652 - 669

Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen.

Harrison S. et al, (2020), Cancer Causes Control, 31, 431 - 449

Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit - the 'Fry-Turnbull' effect.

Lovegrove CE. et al, (2020), BJU Int, 125, 484 - 486

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.

Neal DE. et al, (2020), Eur Urol, 77, 320 - 330

The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies.

Watts EL. et al, (2019), Int J Cancer, 145, 3244 - 3256

Mating induces switch from hormone-dependent to hormone-independent steroid receptor-mediated growth in Drosophila secondary cells.

Leiblich A. et al, (2019), PLoS Biol, 17

Prostatic capsular incision during radical prostatectomy has important oncological implications: a systematic review and meta-analysis.

Philippou Y. et al, (2019), BJU Int, 124, 554 - 566

Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.

Leongamornlert DA. et al, (2019), Eur Urol, 76, 329 - 337

Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study.

Donovan JL. et al, (2019), J Clin Epidemiol, 113, 200 - 213

Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.

Wu X. et al, (2019), Prostate, 79, 1079 - 1089

Runs of homozygosity and testicular cancer risk.

Loveday C. et al, (2019), Andrology, 7, 555 - 564

Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants.

Wu L. et al, (2019), Cancer Res, 79, 3192 - 3204

genetic hazard score to personalize prostate cancer screening, applied to population data

Huynh-Le M-P. et al, (2019), bioRxiv

Proffered abstracts from the 17th Biennial Congress of the Metastasis Research Society.

(2019), Clin Exp Metastasis, 36, 139 - 170

Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.

Bryant RJ. et al, (2019), J Urol, 201, 510 - 519

Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.

Bancroft EK. et al, (2019), BJU Int, 123, 284 - 292

Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR. et al, (2019), Nat Genet, 51

Mating Induces Switch From Hormone-Dependent to – Independent Steroid Receptor-Mediated Growth in Drosophila Prostate-Like Cells

Leiblich A. et al, (2019)

Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk.

Travis RC. et al, (2019), Cancer Res, 79, 274 - 285

9int: SNP interaction pattern search using non-hierarchical additive model set.

Lin H-Y. et al, (2018), Bioinformatics, 34, 4141 - 4150

Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer.

Elliott D. et al, (2018), BJU Int, 122, 970 - 977

Germline variation at 8q24 and prostate cancer risk in men of European ancestry.

Matejcic M. et al, (2018), Nat Commun, 9

Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification?

Bryant RJ. et al, (2018), BJU Int, 122, 794 - 800

ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer.

Lane JA. et al, (2018), Cancer Prev Res (Phila), 11, 687 - 696

andomised controlled trial of Partial prostate Ablation versus Radical prosTatectomy (PART) in intermediate risk, unilateral clinically localised prostate cancer: a feasibility study

Hamdy FC. et al, (2018), Health Technology Assesment, 22, 1 - 96

Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage.

Aleksic T. et al, (2018), Cancer Res, 78, 3497 - 3509

ssociation analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR. et al, (2018), Nat Genet, 50, 928 - 936

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T. et al, (2018), Nat Commun, 9

Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.

Vickers A. et al, (2018), J Urol, 199, 1470 - 1474

prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial.

Donovan JL. et al, (2018), J Clin Epidemiol, 96, 35 - 46

High Levels of Patient Satisfaction in Joint Uro-oncology Clinics to Assist Patient Choice in Early Prostate Cancer and Muscle-invasive Bladder Cancer.

Kiltie AE. et al, (2018), Clin Oncol (R Coll Radiol), 30

Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.

Lophatananon A. et al, (2018), Br J Cancer, 118

Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Mikropoulos C. et al, (2018), Br J Cancer, 118

Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.

Martin RM. et al, (2018), JAMA, 319, 883 - 895

High levels of patient satisfaction in joint uro-oncology clinics to assist patient choice in early prostate cancer and muscle-invasive bladder cancer

Kiltie AE. et al, (2018), Clinical Oncology, 30, e39 - e39

Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV).

Watson EK. et al, (2018), Eur J Oncol Nurs, 32, 73 - 81

Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study.

Leal J. et al, (2018), Cancer Epidemiol, 52, 99 - 105

Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework.

Wilson C. et al, (2018), Trials, 19

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Seibert TM. et al, (2018), BMJ, 360

Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP).

Merriel SWD. et al, (2017), BMJ Open, 7

Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.

Sooriakumaran P. et al, (2017), Eur Urol, 72, 345 - 351

ppraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data.

Camacho N. et al, (2017), PLoS Genet, 13

Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.

Lophatananon A. et al, (2017), Br J Cancer, 117, 734 - 743

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.

Er V. et al, (2017), Cancer Causes Control, 28, 877 - 888

In Defense of Randomized Clinical Trials in Surgery: Let Us Not Forget Archie Cochrane's Legacy.

Catto JWF. et al, (2017), Eur Urol, 71, 820 - 821

Prostate cancer risk related to foods, food groups, macronutrients and micronutrients derived from the UK Dietary Cohort Consortium food diaries.

Lane JA. et al, (2017), Eur J Clin Nutr, 71

Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Helping Decision Making for Patients and Their Physicians.

Hamdy FC. and Donovan JL., (2017), JAMA, 317, 1121 - 1123

SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns.

Lin H-Y. et al, (2017), Bioinformatics, 33, 822 - 833

Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above.

Vickers A. et al, (2017), J Urol, 197, 607 - 613

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.

Johnston TJ. et al, (2017), Eur Urol, 71, 381 - 388

Prostate cancer risk related to foods, food groups, macronutrients and micronutrients derived from the UK Dietary Cohort Consortium food diaries.

Lane JA. et al, (2017), Eur J Clin Nutr, 71, 274 - 283

Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer.

Rao SR. et al, (2017), Br J Cancer, 116, 227 - 236

Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts.

Chen R. et al, (2017), J Urol, 197, 90 - 96

PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.

Southey MC. et al, (2016), J Med Genet, 53, 800 - 811

Prostate-specific antigen patterns in US and European populations: comparison of six diverse cohorts.

Simpkin AJ. et al, (2016), BJU Int, 118, 911 - 918

Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?

Harrison S. et al, (2016), Cancer Causes Control, 27, 1465 - 1474

Circulating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls.

Price AJ. et al, (2016), Eur Urol, 70, 941 - 951

Novel biomarkers for the detection of prostate cancer.

Jakobsen NA. et al, (2016), J Clin Urol, 9, 3 - 10

The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?

Hamdy FC., (2016), BJU Int, 118

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.

Lane A. et al, (2016), BJU Int, 118, 869 - 879

ssessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels.

Bonilla C. et al, (2016), Int J Cancer, 139, 1520 - 1533

Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.

Kar SP. et al, (2016), Cancer Discov, 6, 1052 - 1067

Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance.

Mason MD. et al, (2016), Clin Oncol (R Coll Radiol), 28, e92 - e100

Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee.

Turner EL. et al, (2016), Br J Cancer, 115, 90 - 94

Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up.

Watson E. et al, (2016), BJU Int, 117, E10 - E19

The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer.

Castro E. et al, (2016), Oncologist, 21, 716 - 722

Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).

Thorn JC. et al, (2016), BMJ Open, 6

Bone-directed therapy in prostate cancer: Rationale and novel approaches

Eaton CL. et al, (2016), 223 - 236

Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk.

Travis RC. et al, (2016), Cancer Res, 76, 2288 - 2300

The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium.

Davies NM. et al, (2015), Cancer Causes Control, 26, 1603 - 1616

Genome-wide association study of prostate cancer-specific survival.

Szulkin R. et al, (2015), Cancer Epidemiol Biomarkers Prev, 24, 1796 - 1800

Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies.

Key TJ. et al, (2015), Am J Clin Nutr, 102, 1142 - 1157

The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium

Davies NM. et al, (2015), Cancer Causes and Control, 26, 1603 - 1616

Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

Pashayan N. et al, (2015), Genet Med, 17, 789 - 795

Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.

Amin Al Olama A. et al, (2015), Hum Mol Genet, 24, 5589 - 5602

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial.

Wade J. et al, (2015), BMJ Open, 5

Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: opportunities for lifestyle modification.

Hackshaw-McGeagh LE. et al, (2015), Int J Cancer, 137, 1509 - 1515

Prediction of individual genetic risk to prostate cancer using a polygenic score.

Szulkin R. et al, (2015), Prostate, 75, 1467 - 1474

Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: Opportunities for lifestyle modification

Hackshaw-Mcgeagh LE. et al, (2015), International Journal of Cancer, 137, 1509 - 1515

Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.

Bryant RJ. et al, (2015), J Natl Cancer Inst, 107

Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.

Amin Al Olama A. et al, (2015), Cancer Epidemiol Biomarkers Prev, 24, 1121 - 1129

Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.

van der Poel H. et al, (2015), World J Urol, 33, 907 - 916

Variation between specialist uropatholgists in reporting extraprostatic extension after radical prostatectomy.

Bryant RJ. et al, (2015), J Clin Pathol, 68, 465 - 472

Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer.

Simpkin AJ. et al, (2015), Eur Urol, 67, 993 - 1005

Systematic review and meta-analysis of factors determining change to radical treatment in active surveillance for localized prostate cancer

Simpkin AJ. et al, (2015), European Urology, 67, 993 - 1005

The genomic diversity of prostate cancer: our Achilles heel explored.

Bryant RJ. et al, (2015), Eur Urol, 67, 823 - 824

chievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.

Fizazi K. et al, (2015), Eur Urol, 67, 904 - 912

The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers.

Cremers RG. et al, (2015), Urol Oncol, 33, 202.e19 - 202.e28

chievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: Introducing the prostate cancer consortium in Europe

Fizazi K. et al, (2015), European Urology, 67, 904 - 912

Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes.

Kote-Jarai Z. et al, (2015), Ann Oncol, 26, 756 - 761

Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187.

Reeves KJ. et al, (2015), Int J Cancer, 136, 1731 - 1740

Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer.

Stegeman S. et al, (2015), Cancer Discov, 5, 368 - 379

Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial.

Wade J. et al, (2015), BMC Health Serv Res, 15

Gleason drift in the NIHR ProtecT study.

Oxley J. et al, (2015), Histopathology, 66, 438 - 446

ssociations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study.

Gilbert R. et al, (2015), Cancer Causes Control, 26, 205 - 218

ssociations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case–control study

Gilbert R. et al, (2015), Cancer Causes and Control, 26, 205 - 218

Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).

Williams NJ. et al, (2015), BMC Med Res Methodol, 15

Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial - Lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer) Data collection, quality, and reporting

Williams NJ. et al, (2015), BMC Medical Research Methodology, 15

Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA.

Drayton RM. et al, (2015), Cancer Epidemiol Biomarkers Prev, 24, 268 - 275

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy.

Gilbert R. et al, (2015), PLoS One, 10

Men with locally advanced prostate cancer excluded from the ProtecT Trial: early detection produces better outcomes

Johnston T. et al, (2015), BJU INTERNATIONAL, 115, 60 - 60

THE PROTON-ASSISTED AMINO ACID TRANSPORTER 4 (PAT4/SLC36A4) IS UP-REGULATED IN PROSTATE CANCER

Stevens D. et al, (2015), JOURNAL OF UROLOGY, 193, E677 - E677

ltered expression of markers of epithelial-to-mesenchymal transition at the extraprostatic extension component of locally invasive prostate cancers

Verrill C. et al, (2015), BJU INTERNATIONAL, 115, 69 - 69

ltered expression of markers of epithelial-to-mesenchymal transition at the extraprostatic extension component of locally invasive prostate cancers

Verrill C. et al, (2015), BJU INTERNATIONAL, 115, 8 - 8

Men's knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study.

Horwood JP. et al, (2014), BMC Cancer, 14

Nuclear iASPP may facilitate prostate cancer progression.

Morris EV. et al, (2014), Cell Death Dis, 5

dherence to dietary and lifestyle recommendations and prostate cancer risk in the prostate testing for cancer and treatment (ProtecT) trial.

Er V. et al, (2014), Cancer Epidemiol Biomarkers Prev, 23, 2066 - 2077

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

Bancroft EK. et al, (2014), Eur Urol, 66, 489 - 499

BMP-regulated exosomes from Drosophila male reproductive glands reprogram female behavior.

Corrigan L. et al, (2014), J Cell Biol, 206, 671 - 688

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

Bancroft EK. et al, (2014), Eur Urol, 66, 489 - 499

Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences.

Mills N. et al, (2014), Trials, 15

Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies.

Leal J. et al, (2014), Int J Urol, 21, 786 - 792

The intellectual challenges and emotional consequences of equipoise contributed to the fragility of recruitment in six randomized controlled trials.

Donovan JL. et al, (2014), J Clin Epidemiol, 67, 912 - 920

Reply to Behnam Shakiba's letter to the editor re: Philipp Dahm, James N'Dow, Lars Holmberg, Freddie Hamdy. The future of randomised controlled trials in urology. Eur Urol 2014;66:1-3.

Dahm P. et al, (2014), Eur Urol, 66

Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies.

Knipe DW. et al, (2014), Cancer Epidemiol Biomarkers Prev, 23, 1356 - 1365

PROSPECTIV-a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial.

Watson E. et al, (2014), BMJ Open, 4

The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals.

Avery KNL. et al, (2014), BMC Fam Pract, 15

The importance of dietary change for men diagnosed with and at risk of prostate cancer: A multi-centre interview study with men, their partners and health professionals

Avery KNL. et al, (2014), BMC Family Practice, 15

Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.

Cazier J-B. et al, (2014), Nat Commun, 5

Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.

Ankerst DP. et al, (2014), World J Urol, 32, 185 - 191

Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer.

Saunders EJ. et al, (2014), PLoS Genet, 10

Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: Results from the prostate biopsy collaborative group

Ankerst DP. et al, (2014), World Journal of Urology, 32, 185 - 191

Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis.

Weng P-H. et al, (2014), PLoS One, 9

Corrigendum: Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.

Cazier JB. et al, (2014), Nat Commun, 5

Corrigendum: Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.

Cazier JB. et al, (2014), Nat Commun, 5

The intellectual challenges and emotional consequences of equipoise contributed to the fragility of recruitment in six randomized controlled trials

Donovan JL. et al, (2014), Journal of Clinical Epidemiology, 67, 912 - 920

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study

Bancroft EK. et al, (2014), European Urology, 66, 489 - 499

ctive monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: Study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial

Lane JA. et al, (2014), The Lancet Oncology, 15, 1109 - 1118

Three-dimensional scaffolds: An in vitro strategy for the biomimetic modelling of in vivo tumour biology

Sharma A. et al, (2014), Journal of Materials Science, 49, 5809 - 5820

DHERENCE TO DIETARY AND LIFESTYLE RECOMMENDATIONS AND PROSTATE CANCER RISK IN THE PROSTATE TESTING FOR CANCER AND TREATMENT (PROTECT) TRIAL

Er V. et al, (2014), ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 10, 11 - 11

genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk.

Pooley KA. et al, (2013), Hum Mol Genet, 22, 5056 - 5064

Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression.

Ricci E. et al, (2013), Prostate, 73, 1738 - 1746

Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men: the PROBASE trial.

Arsov C. et al, (2013), Eur Urol, 64, 873 - 875

Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression.

Wade J. et al, (2013), J Clin Oncol, 31, 4235 - 4241

Re: Flexible cystoscopy findings in patients investigated for profound lower urinary tract symptoms, recurrent urinary tract infection, and pain.

Schaeffer EM., (2013), J Urol, 190

Corrigendum to Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression [Human Molecular Genetics, 22, (2013), 2520-2528] doi:10.1093/hmg/ddt086

Zsofia KJ. et al, (2013), Human Molecular Genetics, 22

Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer.

Mathew G. et al, (2013), Sci Rep, 3

Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis.

Orozco G. et al, (2013), BJU Int, 111, 1148 - 1155

Using genetic proxies for lifecourse sun exposure to assess the causal relationship of sun exposure with circulating vitamin d and prostate cancer risk.

Bonilla C. et al, (2013), Cancer Epidemiol Biomarkers Prev, 22, 597 - 606

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair.

Groselj B. et al, (2013), Br J Cancer, 108, 748 - 754

Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage signalling and repair

Groselj B. et al, (2013), British Journal of Cancer, 108, 748 - 754

ssociations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring.

Gilbert R. et al, (2013), Eur J Cancer Prev, 22, 121 - 125

meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.

Amin Al Olama A. et al, (2013), Hum Mol Genet, 22, 408 - 415

Very low PSA concentrations and deletions of the KLK3 gene.

Rodriguez S. et al, (2013), Clin Chem, 59, 234 - 244

DNA damage response in peritumoral regions of oesophageal cancer microenvironment.

He H. et al, (2013), Carcinogenesis, 34, 139 - 145

Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study.

Rowlands M-A. et al, (2013), Cancer Causes Control, 24, 39 - 45

Flexible cystoscopy findings in patients investigated for profound lower urinary tract symptoms, recurrent urinary tract infection, and pain.

Howles S. et al, (2012), J Endourol, 26, 1468 - 1472

Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma.

McKee CM. et al, (2012), J Clin Invest, 122, 4025 - 4036

ssociations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade.

Gilbert R. et al, (2012), Cancer Causes Control, 23, 1865 - 1873

Evaluating genetic risk for prostate cancer among Japanese and Latinos.

Cheng I. et al, (2012), Cancer Epidemiol Biomarkers Prev, 21, 2048 - 2058

ssociations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring.

Burton AJ. et al, (2012), Cancer Epidemiol Biomarkers Prev, 21, 1877 - 1885

cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom.

Young NJ. et al, (2012), Cancer Causes Control, 23, 907 - 917

Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.

Ying S. et al, (2012), Cancer Res, 72, 2814 - 2821

cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom

Young NJ. et al, (2012), Cancer Causes and Control, 23, 907 - 917

Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases.

Colombel M. et al, (2012), Prostate, 72, 713 - 720

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.

Roobol MJ. et al, (2012), World J Urol, 30, 149 - 155

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.

Ankerst DP. et al, (2012), World J Urol, 30, 181 - 187

Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study.

Gilbert R. et al, (2012), Cancer Causes Control, 23, 575 - 588

Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT.

Rowlands M-A. et al, (2012), Cancer Res, 72, 503 - 515

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.

Rosario DJ. et al, (2012), BMJ, 344

iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.

Rehman I. et al, (2012), PLoS One, 7

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study

Rosario DJ. et al, (2012), BMJ (Online), 344

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study

Rosario DJ. et al, (2012), BMJ, 344

Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study.

Gilbert R. et al, (2012), Cancer causes & control : CCC, 23, 575 - 588

Circulating microRNAs are associated with the development and progression of prostate cancer

Bryant RJ. et al, (2012), EUROPEAN UROLOGY SUPPLEMENTS, 11, E435 - U952

MEN WITH PROSTATE CANCER MAKE POSITIVE DIETARY CHANGES FOLLOWING TREATMENT IN A RANDOMISED TRIAL: A PROSPECTIVE COHORT STUDY

Avery KNL. et al, (2012), JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 66, A40 - A41

ddressing patient treatment preferences at trial recruitment.

Mills N. et al, (2011), Trials, 12 Suppl 1

Understanding factors influencing questionnaire response rates to maximise retention in a long term complex intervention trial

Lane AJ. et al, (2011), Trials, 12

Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK.

Down L. et al, (2011), BJU Int, 108, 1409 - 1414

Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.

Williams N. et al, (2011), BJU Int, 108, 1402 - 1408

Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance.

Lane JA. et al, (2011), J Clin Epidemiol, 64, 628 - 636

Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance

Lane JA. et al, (2011), Journal of Clinical Epidemiology, 64, 628 - 636

nalysis of blood-derived circulating microvesicles for microRNA biomarkers of metastatic and nonmetastatic prostate cancer.

Hamdy FC. et al, (2011), J Clin Oncol, 29

MicroRNA in prostate, bladder, and kidney cancer: a systematic review.

Catto JWF. et al, (2011), Eur Urol, 59, 671 - 681

MicroRNA in prostate, bladder, and kidney cancer: A systematic review

Catto JWF. et al, (2011), European Urology, 59, 671 - 681

Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence.

Pashayan N. et al, (2011), Cancer Epidemiol, 35, 139 - 144

ssociations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).

Murad AS. et al, (2011), Int J Cancer, 128, 1442 - 1448

PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression.

Pashayan N. et al, (2011), Int J Cancer, 128, 1462 - 1470

Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer.

Dudziec E. et al, (2011), Clin Cancer Res, 17, 1287 - 1296

Use of macrophages to target therapeutic adenovirus to human prostate tumors.

Muthana M. et al, (2011), Cancer Res, 71, 1805 - 1815

ssociation of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.

Dimitropoulou P. et al, (2011), Br J Cancer, 104, 875 - 881

ssociation of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study

Dimitropoulou P. et al, (2011), British Journal of Cancer, 104, 875 - 881

cupuncture in urological practice--a survey of urologists in England.

Tempest H. et al, (2011), Complement Ther Med, 19, 27 - 31

ssociation of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).

Turner EL. et al, (2011), Int J Cancer, 128, 440 - 446

The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?

Collin SM. et al, (2011), Int J Mol Epidemiol Genet, 2, 316 - 327

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.

Mitra AV. et al, (2011), BJU Int, 107, 28 - 39

ssociation between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data.

Batra J. et al, (2011), PLoS One, 6

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study

Catto JWF. et al, (2011), British Journal of Cancer, 105, 931 - 937

comparison of prostate cancer survival in England, Norway and Sweden: A population-based study

Holmberg L. et al, (2011), Cancer Epidemiology

nalysis of blood-derived circulating microvesicles for microRNA biomarkers of metastatic and nonmetastatic prostate cancer.

Hamdy FC. et al, (2011), JOURNAL OF CLINICAL ONCOLOGY, 29

URINARY MICRORNA IN BLADDER CANCER - A POTENTIAL DIAGNOSTIC TOOL

Miah S. et al, (2011), EUROPEAN UROLOGY SUPPLEMENTS, 10, 81 - 81

SSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING

Burton AJG. et al, (2011), EUROPEAN UROLOGY SUPPLEMENTS, 10, 237 - 237

Prostate cancer cell homing to bone invivo is modulated by zoledronic

Reeves KJ. et al, (2011), CANCER RESEARCH, 71

SSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING

Burton A. et al, (2011), JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 65, A229 - A229

LCOHOL AND PROSTATE CANCER RISK: A MENDELIAN RANDOMISATION APPROACH

Zuccolo L. et al, (2011), JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 65, A60 - A60

The homing of prostate cancer to bone in vivo is modulated by Zoledronic acid

Reeves KJ. et al, (2011), BONE, 48, S45 - S46

More publications

Cookies on this website